Our Members
The State of Mexico is Mexico’s foremost pharmaceutical production hub.The state is home to 111 pharmaceutical companies generating 18.4% of the country’s total pharmaceutical output and employing over 14,300 specialized professionals, making it the deepest talent pool in the sector outside the capital.
The state anchors its life sciences ecosystem in a dedicated Chemical-Pharmaceutical and Medical Device Corridor, one of seven Strategic Productive Corridors designed to accelerate investment and industry clustering. This infrastructure is backed by 228 industrial developments, over 3,000 educational campuses, and leading research institutions including UNAM, ITESM, and UAEMex.
As Mexico’s 2nd largest recipient of foreign direct investment, with $6.37 billion USD attracted between 2023 and 2025, Estado de México offers pharmaceutical companies a uniquely competitive combination: proven manufacturing scale, regulatory proximity to the U.S. market, and a world-class scientific workforce ready to grow.
Dinamys Bioworks is an early-phase ATMP CDMO based in Monterrey, Nuevo León, Mexico, designed to help overseas biotech companies de-risk the translation of cell and advanced therapies into early clinical manufacturing. Dinamys integrates GMP manufacturing, CMC strategy, technology transfer, process development, translational QC, potency-oriented development, and quality systems to support companies seeking a reliable path toward first-in-human and Phase I/II programs.
By operating from Mexico, Dinamys offers a cost-efficient, nearshoring-ready platform for companies that want to test clinical, regulatory, and market assumptions in Latin America before making larger infrastructure or manufacturing commitments in higher-cost regions. The company aims to become a strategic bridge between global biotech innovation and Latin American clinical-market access, combining scientific depth, regulatory readiness, operational discipline, and execution-focused manufacturing for advanced therapies.
Grupo Neolpharma is a Mexican pharmaceutical group dedicated to the research, development, manufacturing, and distribution of high-quality medicines. Operating through subsidiaries Psicofarma, NeolSyM, and Laboratorios Alpharma, the Group holds a portfolio across 10 therapeutic areas, including neurosciences, oncology, cardiovascular, and antibiotics.
Its manufacturing infrastructure includes specialized pharmaceutical plants, API synthesis facilities, a biotechnology plant, and a pilot plant for development and scale-up — all operating under cGMP standards.
Innovation is a core pillar of the Group’s strategy. Through its Academy–Industry Innovation Office, Neolpharma advances research in psychiatric and neurological diseases, novel drug delivery systems, and drug combinations, with Transkrip — an epigenetic therapy for oncology — as a flagship case of translational medicine.
Udelá is a leading company in the development and implementation of regulatory strategies for the health sector in Mexico and Latin America. We support our customers throughout the entire lifecycle of their products, from regulatory approval to compliance and market expansion.
Our team brings solid experience in regulatory affairs and close interaction with health authorities, allowing us to anticipate challenges, provide practical solutions, and facitilate access to highly regulated markets.
At Udelá, we work closely with our customers, focusing on delivering reliable and efficient solutions to ensure timely access to safe and high-quality health products.
Founded in 1943, Silanes is a Mexican pharmaceutical company focused on innovation, value-added medicines, and strategic partnerships. With more than 82 years of experience, we develop, manufacture, and commercialize differentiated healthcare solutions across key therapeutic areas, including Cardiovascular, Analgesia, CNS, Diabetes, Respiratory, Urology, Gastroenterology, Antivenoms, and Vitamins. Our business model combines strong in-house R&D, a portfolio supported by more than 150 patents, and robust manufacturing capabilities with global-standard regulatory compliance.
Through alliances with international partners, Silanes continues to expand its presence beyond Mexico and strengthen its role as a reliable partner for licensing, co-development, and other strategic collaborations. At BIO San Diego 2026, we aim to connect with partners who share our commitment to bringing innovative and high-value therapies to patients across global markets.
UDIBI is Mexico’s premier biotechnology lab specialized in the research, development and evaluation of biotherapeutics, biosimilars and advanced therapies. We offer a broad range of scientific and regulatory services spanning antibody discovery, preclinical studies, analytical testing, biosimilar assessment and regulatory consulting.
UDIBI holds authorizations from the Mexican regulatory agency (COFEPRIS) asa Third-Party Preclinical Biocomparability Unit and Certified Testing Laboratory, UDIBI combines world-class infrastructure with deep regulatory expertise. Through the ALTHEA Libraries™ platform, developed in alliance with GlobalBio Inc., we lead antibody discovery innovation in Latin America. We are committed to transforming science into real health solutions.
Laboratorios Liomont is a leading pharmaceutical company in Mexico with operations dating back to 1938. The company commercializes pharmaceutical products across Latin America, the United States, and Europe.
Liomont is engaged in the development, in licensing, and out licensing of innovative and late stage pharmaceutical products, with a growing focus on biologics and biosimilars. The company has developed a biosimilar asset, LT01, which has successfully completed clinical development and met clinical biosimilarity criteria. Submission to the European Medicines Agency (EMA) is planned for the end of 2026.
Liomont also offers GMP manufacturing capabilities, including sterile fill finish in vials for liquid and lyophilized products, as well as a cell culture facility suitable for GMP production of clinical trial batches. The company is actively seeking strategic partners for biosimilar and biologics development, as well as contract manufacturing collaborations.
Saya Biologics is an AI-powered biosimilars company building an integrated development and commercialization platform across Mexico and the United States. The company pursues growth through co-development and licensing, combining partner selection, portfolio strategy, and execution discipline to bring high-quality biosimilars to market. Established in 2022, Saya Biologics has already assembled a robust portfolio, including four approvals in 2026, demonstrating the ability to convert programs into real-world outcomes.
Commercialization is built in from day one, linking development choices to market access strategy, pricing and contracting readiness, demand and supply planning, and launch execution. Saya Biologics works with experienced partners across manufacturing, clinical, regulatory, and market access, applying AI and operational excellence to scale a repeatable, high-impact biosimilars platform.
CTR Scientific is a Mexican company founded in 1969, with over 550 employees, 15 offices across Mexico, and 5 distribution centers. Our commercial team includes more than 100 sales representatives and sales assistants, 27 product specialists, and 15 field service engineers. We also operate 2 accredited metrology laboratories. CTR supplies instruments, reagents, consumables, and services — including operational support and regulatory consulting. We serve four market segments: industrial, clinical diagnostics, research, and education.
The quality of our Fetal Bovine Serum is endorsed by the traceability of the raw material, its production process, due to compliance with levels of growth factors endotoxins, osmolality, its low protein content it does have an effect of not lysing cells in culture and not interfere with immunoassays; as well as its high-performance individual in cell culture. Our Fetal Bovine Serum has a vast range of applications in the areas of research, manufacturing and control of vaccines, biotechnological drugs for human and animal consumption. Using our patented technology, we crystallize FBS—thereby eliminating the ultra-freezing chain, substantially reducing costs, and ensuring it is cruelty-free.
Our portfolio encompasses more than 70 medicines and devices across a range of areas including reproductive health, cardiovascular disease, neurology, dermatology, autoimmune, and respiratory conditions. We bring these important therapies to more than 140 markets around the world.
Avant Santé Research Center S.A. de C.V. is a US FDA-audited CRO based in Mexico, providing integrated clinical development and regulatory solutions for pharmaceutical biotechnology, and healthcare companies.
Avant Santé offers comprehensive services including:
With extensive multi-regulatory experience, FDA-audited facilities, and access to a broad investigator and patient network, Avant Santé helps sponsors accelerate development timelines, optimize regulatory pathways, and achieve efficient market access in both global and emerging markets.
PiSA® Farmaceutica is a Mexican company with almost 80 years of history dedicated to the manufacturing, marketing and distribution of health product. Our portfolio consists in more than 1,500 brands of medicines distributed through 17 therapeutic areas.
Currently, we are a team with over 30,000 collaborators dedicated to health care throughout the American continent.
Hold the Electrolit®️ brand which is the 4th biggest brand in Hydration and Isotonic beverages category and has a presence in 14 countries.
Now available in Europe (Spain).
We have our own network of 7 warehouses throughout the country and a fleet of 400 units, making us the best partner and supplier to healthcare organizations, as we are fully integrated into the future, including last mile distribution. Committed to offering high quality products, we have certifications in:
The growth at PiSA®️ Farmacéutica has been a constant due to its human capital. We are committed to excellence, aware that each of our actions and activities are to fulfill our reason for being: “A Life at the Service of Life.”
Fundación INCIDE is a Mexican non-profit organization dedicated to connecting industry, academia, government, and innovation ecosystems to accelerate the development, transfer, and commercialization of science-based technologies in health, biotechnology, pharmaceuticals, and health tech. Through strategic intelligence, technology scouting, open innovation, and international collaboration initiatives, INCIDE promotes high-impact partnerships and supports the growth of innovative projects with global potential, positioning Mexico as an emerging hub for biotech and pharmaceutical innovation at events such as BIO International Convention 2026.
Carnot Laboratories is one of Latin America’s leading specialty pharmaceutical groups, focused on accelerating the development, registration, and commercialization of innovative therapies. With direct commercial operations in Mexico, Brazil, Colombia, and Peru, more than 600 field-based professionals, strong regulatory capabilities, and annual revenues exceeding USD 250 million, Carnot offers partners a unique platform to maximize the value of innovative assets throughout the region.
The company actively pursues licensing, co-development, joint ventures, and strategic investment opportunities in innovative pharmaceuticals, biologics, specialty care, and differentiated healthcare technologies.
ITC is a Latin American biotechnology platform advancing regenerative medicine through cell-based technologies, translational science, and quality-driven execution. With specialized expertise in mesenchymal stromal cells, secretome, extracellular vesicles, tissue processing, cryobanking, and advanced analytical support, ITC integrates scientific development with real-world clinical application. Its infrastructure includes ISO-classified laboratories, GMP-aligned workflows, full traceability, and controlled process architecture designed to support reproducible, scalable, and clinically relevant solutions. ITC’s work is strengthened by regional clinical integration, regulatory awareness, and a patent-pending platform that protects its core manufacturing logic for MSCs, secretome, and extracellular vesicles. More than a service provider, ITC positions itself as an innovation engine for regenerative medicine in LATAM, transforming cellular science into structured therapeutic platforms with impact, reliability, and long-term strategic value.
The Mexico City Ministry of Economic Development (SEDECO) is driving a strategic initiative to establish Mexico City as the leading biotechnology and life sciences hub in Latin America. Leveraging the city’s world-class research institutions, universities, hospitals, and growing innovation ecosystem, SEDECO works to attract investment, foster public-private partnerships, accelerate technology transfer, and support the commercialization of scientific innovation.
As part of this effort, SEDECO actively promotes international collaboration with biotechnology companies, research centers, investors, contract development and manufacturing organizations (CDMOs), and industry associations. By connecting global stakeholders with Mexico City’s scientific and entrepreneurial ecosystem, SEDECO seeks to strengthen the region’s capabilities in biopharmaceuticals, advanced therapies, medical technologies, and health innovation. Through these initiatives, Mexico City is positioning itself as a gateway for biotechnology growth, manufacturing, and innovation across Mexico and Latin America
EPIC CRO is a clinical research organization based in Mexico, committed to advancing the development of innovative and generic therapies through high-quality, efficient, and regulatory-compliant research services. We serve as a strategic partner for pharmaceutical companies, biotechnology firms, and healthcare organizations seeking reliable execution of clinical trials and bioequivalence studies in Latin America.
Built on a foundation of scientific rigor, operational excellence, and ethical responsibility, EPIC CRO is designed to support sponsors from study concept through execution and closeout. Through our strategic alliance with a third-authorized partner and specialized research centers, we offer integrated services that streamline study startup, strengthen regulatory coordination, and ensure consistent oversight throughout the clinical development process.
Our capabilities include protocol feasibility, site selection, regulatory submissions, project management, site operations, patient recruitment, monitoring, data management, and study closeout. For bioequivalence studies, we provide operational support focused on efficiency, quality, and compliance, helping sponsors generate dependable data to support product registration and market access.
At EPIC CRO, we understand the importance of speed, quality, and trust in today’s competitive research environment. Our model is built to reduce operational complexity, improve communication across stakeholders, and deliver high-value services tailored to sponsor needs. We are committed to maintaining the highest standards of Good Clinical Practice, data integrity, and participant safety in every study we support.
As the clinical research landscape continues to expand across North America and Latin America, EPIC CRO is positioned to contribute meaningfully to global innovation by offering a strong regional presence, local expertise, and a collaborative approach to research execution. Our goal is to become a trusted partner for companies attending BIO San Diego 2026 who are looking to expand into Mexico and the broader Latin American market.
EPIC CRO’s vision is to support the future of medicine by enabling faster, more efficient, and more accessible clinical development pathways. We believe that successful research is built on collaboration, transparency, and excellence — and we are ready to work alongside sponsors, investigators, and strategic partners to bring that vision to life.
Pragmatec is a Mexico-based innovation and internationalization consulting firm specialized in the health, biotech, pharma, and life sciences sectors. The organization supports companies, governments, clusters, universities, and innovation agencies in building strategic connections between Mexico and international ecosystems. Its work includes market exploration programs, technology transfer, business matchmaking, innovation scouting, regulatory and commercialization support, and ecosystem engagement for biotech, pharmaceutical, medical device, and digital health organizations.
Pragmatec has coordinated international missions and collaboration initiatives with partners from Canada, Europe, and Latin America, facilitating interactions with hospitals, pharmaceutical companies, research centers, startups, and public institutions. Through its extensive network and sector expertise,
Pragmatec helps organizations identify opportunities for validation, partnerships, market entry, and long-term collaboration within the Mexican life sciences ecosystem